Jazz Pharmaceuticals Plc Financials
Jazz Pharmaceuticals Plc (JAZZ) reported $4.3B in revenue for fiscal year 2025, up 4.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Accounting profit and cash generation diverged as deleveraging continued despite a reported FY2025 operating loss.
FY2025’s biggest disconnect is that operating margin fell from17.6% to-10.1% while operating cash flow stayed near$1.4B ; that combination suggests the reported loss was far less cash-destructive than the income statement alone implies. At the same time, long-term debt fell by about$1.7B and cash dropped by about$1.0B , showing that much of that cash generation was redirected toward balance-sheet repair rather than left idle.
Liquidity tightened: the current ratio fell from 4.5x to 1.9x as current liabilities rose to
The profit reversal looks more like a cost-structure break than a sales problem: revenue still increased in FY2025, but selling and administrative expense expanded by about
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Jazz Pharmaceuticals Plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Jazz Pharmaceuticals Plc has an operating margin of -10.1%, meaning the company loses $10 on every $100 of revenue. This results in a profitability score of 40/100. This is down from 17.6% the prior year.
Jazz Pharmaceuticals Plc's revenue grew a modest 4.9% year-over-year to $4.3B. This slow but positive growth earns a score of 52/100.
Jazz Pharmaceuticals Plc has a moderate D/E ratio of 1.00. This balance of debt and equity financing earns a leverage score of 46/100.
Jazz Pharmaceuticals Plc's current ratio of 1.86 indicates adequate short-term liquidity, earning a score of 54/100. The company can meet its near-term obligations, though with limited headroom.
Jazz Pharmaceuticals Plc converts 30.4% of revenue into free cash flow ($1.3B). This strong cash generation earns a score of 95/100.
Jazz Pharmaceuticals Plc posts a -8.3% return on equity (ROE), meaning it loses $8 for every $100 of shareholders' equity. This results in a returns score of 31/100. This is down from 13.7% the prior year.
Jazz Pharmaceuticals Plc scores 1.87, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($16.5B) relative to total liabilities ($7.3B). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Jazz Pharmaceuticals Plc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Jazz Pharmaceuticals Plc reported a net loss of $356.1M while generating $1.4B in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Jazz Pharmaceuticals Plc generated $4.3B in revenue in fiscal year 2025. This represents an increase of 4.9% from the prior year.
Jazz Pharmaceuticals Plc's EBITDA was -$388.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 151.9% from the prior year.
Jazz Pharmaceuticals Plc reported -$356.1M in net income in fiscal year 2025. This represents a decrease of 163.6% from the prior year.
Jazz Pharmaceuticals Plc earned -$5.84 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 167.5% from the prior year.
Cash & Balance Sheet
Jazz Pharmaceuticals Plc generated $1.3B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 4.5% from the prior year.
Jazz Pharmaceuticals Plc held $1.4B in cash against $4.3B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Jazz Pharmaceuticals Plc's operating margin was -10.1% in fiscal year 2025, reflecting core business profitability. This is down 27.7 percentage points from the prior year.
Jazz Pharmaceuticals Plc's net profit margin was -8.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 22.1 percentage points from the prior year.
Jazz Pharmaceuticals Plc's ROE was -8.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 21.9 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Jazz Pharmaceuticals Plc invested $782.7M in research and development in fiscal year 2025. This represents a decrease of 11.5% from the prior year.
Jazz Pharmaceuticals Plc spent $125.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 59.9% from the prior year.
Jazz Pharmaceuticals Plc invested $58.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 54.3% from the prior year.
JAZZ Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6B | $4.3B+4.9% | $4.1B+6.1% | $3.8B+4.8% | $3.7B+18.3% | $3.1B+30.9% | $2.4B+9.3% | $2.2B+14.3% | $1.9B+16.8% | $1.6B+8.8% | $1.5B+12.3% | $1.3B+13.0% | $1.2B+34.4% | $872.4M+48.9% | $586.0M+115.2% | $272.3M |
| R&D Expenses | $815.6M | $782.7M-11.5% | $884.0M+4.0% | $849.7M+43.9% | $590.5M+16.7% | $505.7M+50.8% | $335.4M+11.9% | $299.7M+32.3% | $226.6M+14.2% | $198.4M+22.3% | $162.3M+20.0% | $135.3M+58.8% | $85.2M+104.6% | $41.6M+103.3% | $20.5M+45.0% | $14.1M |
| SG&A Expenses | $1.7B | $1.8B+30.6% | $1.4B+3.1% | $1.3B-5.2% | $1.4B-2.4% | $1.5B+69.9% | $854.2M+15.9% | $736.9M+7.8% | $683.5M+25.6% | $544.2M+8.2% | $502.9M+12.0% | $449.1M+10.6% | $406.1M+33.5% | $304.3M+35.9% | $223.9M+105.5% | $108.9M |
| Operating Income | $896.9M | -$430.2M-160.0% | $716.6M+23.9% | $578.6M+983.0% | -$65.5M-138.5% | $170.3M-55.0% | $378.1M-29.0% | $532.4M-13.4% | $614.8M+16.3% | $528.8M-10.6% | $591.7M+16.4% | $508.2M+159.8% | $195.6M-42.5% | $340.3M+72.0% | $197.8M+54.8% | $127.8M |
| Interest Expense | N/A | N/A | N/A | $32.8M0.0% | $32.8M-63.5% | $89.9M+2.6% | $87.6M+40.2% | $62.5M+10.2% | $56.7M+50.0% | $37.8M+37.5% | $27.5M+3.8% | $26.5M | N/A | N/A | N/A | $1.7M |
| Income Tax | -$213.2M | -$272.4M-198.0% | -$91.4M+23.8% | -$119.9M+24.4% | -$158.6M-173.4% | $216.1M+544.8% | $33.5M+145.8% | -$73.2M-191.3% | $80.2M+267.9% | -$47.7M-135.3% | $135.2M+27.1% | $106.4M+12.9% | $94.2M+2.8% | $91.6M+209.4% | -$83.8M | $0 |
| Net Income | $940.8M | -$356.1M-163.6% | $560.1M+35.0% | $414.8M+285.1% | -$224.1M+32.0% | -$329.7M-238.2% | $238.6M-54.4% | $523.4M+17.1% | $447.1M-8.4% | $487.8M+22.9% | $396.8M+20.4% | $329.5M+464.4% | $58.4M-73.0% | $216.3M-25.0% | $288.6M+130.9% | $125.0M |
| EPS (Diluted) | — | -$5.84-167.5% | $8.65+41.8% | $6.10+270.4% | -$3.58+35.1% | -$5.52-230.8% | $4.22-53.6% | $9.09+24.5% | $7.30-8.3% | $7.96+24.2% | $6.41+22.6% | $5.23+462.4% | $0.93-73.5% | $3.51-26.7% | $4.79+79.4% | $2.67 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
JAZZ Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.7B-2.9% | $12.0B+5.4% | $11.4B+5.2% | $10.8B-11.9% | $12.3B+88.2% | $6.5B+18.0% | $5.5B+6.4% | $5.2B+1.6% | $5.1B+6.7% | $4.8B+44.0% | $3.3B-0.2% | $3.3B+49.2% | $2.2B+13.8% | $2.0B+675.5% | $253.6M |
| Current Assets | $4.2B-10.0% | $4.6B+34.7% | $3.4B+31.8% | $2.6B-0.2% | $2.6B-8.0% | $2.8B+74.2% | $1.6B+32.1% | $1.2B+27.4% | $968.3M+29.4% | $748.1M-40.5% | $1.3B+23.8% | $1.0B+17.5% | $864.6M+56.8% | $551.6M+177.0% | $199.1M |
| Cash & Equivalents | $1.4B-42.3% | $2.4B+60.2% | $1.5B+70.9% | $881.5M+49.0% | $591.4M-44.1% | $1.1B+66.0% | $637.3M+105.8% | $309.6M-19.8% | $386.0M+5.5% | $366.0M-63.0% | $988.8M+44.6% | $684.0M+7.5% | $636.5M+64.4% | $387.2M+371.8% | $82.1M |
| Inventory | $417.0M-13.2% | $480.4M-19.5% | $597.0M-16.4% | $714.1M-33.4% | $1.1B+1024.5% | $95.4M+21.4% | $78.6M+48.4% | $53.0M+22.5% | $43.2M+27.0% | $34.1M+75.1% | $19.5M-35.2% | $30.0M+4.8% | $28.7M+8.1% | $26.5M+578.6% | $3.9M |
| Accounts Receivable | $830.7M+15.9% | $716.8M+1.6% | $705.8M+8.3% | $651.5M+15.6% | $563.4M+42.1% | $396.5M+11.4% | $356.0M+34.9% | $263.8M+17.7% | $224.1M-4.3% | $234.2M+11.7% | $209.7M+12.5% | $186.4M+49.3% | $124.8M+65.3% | $75.5M+119.6% | $34.4M |
| Goodwill | $1.8B+6.6% | $1.7B-2.1% | $1.8B+3.6% | $1.7B-7.4% | $1.8B+90.7% | $958.3M+4.2% | $920.0M-0.8% | $927.6M-2.1% | $947.5M+6.0% | $893.8M+36.0% | $657.1M-6.5% | $702.7M+56.0% | $450.5M+1.8% | $442.6M+1058.2% | $38.2M |
| Total Liabilities | $7.3B-7.3% | $7.9B+3.4% | $7.7B-1.2% | $7.7B-7.0% | $8.3B+189.7% | $2.9B+18.5% | $2.4B-0.7% | $2.4B+1.5% | $2.4B-17.5% | $2.9B+79.7% | $1.6B-17.4% | $2.0B+108.7% | $942.7M+11.5% | $845.2M+1290.5% | $60.8M |
| Current Liabilities | $2.2B+115.9% | $1.0B-32.4% | $1.5B+64.7% | $933.2M+15.3% | $809.3M+23.8% | $653.7M+79.4% | $364.5M+5.5% | $345.5M+17.5% | $293.9M+14.2% | $257.4M+13.6% | $226.6M+4.5% | $216.8M+6.3% | $204.0M+6.5% | $191.5M+262.3% | $52.9M |
| Long-Term Debt | $4.3B-28.8% | $6.1B+19.0% | $5.1B-10.3% | $5.7B-5.4% | $6.0B+225.6% | $1.8B+17.5% | $1.6B+0.7% | $1.6B+1.5% | $1.5B-22.7% | $2.0B+73.2% | $1.2B-13.7% | $1.3B+144.9% | $544.4M+27.5% | $427.1M | $0 |
| Total Equity | $4.3B+5.5% | $4.1B+9.5% | $3.7B+21.1% | $3.1B-22.2% | $4.0B+8.3% | $3.7B+17.6% | $3.1B+12.8% | $2.8B+1.6% | $2.7B+44.5% | $1.9B+10.0% | $1.7B+24.4% | $1.4B+5.8% | $1.3B+15.5% | $1.1B+481.6% | $192.8M |
| Retained Earnings | $646.1M-42.7% | $1.1B+28.3% | $878.7M+19.8% | $733.6M-11.6% | $830.2M-28.4% | $1.2B+8.6% | $1.1B+27.0% | $841.0M-8.4% | $918.0M+73.6% | $528.9M+74.7% | $302.7M+772.2% | $34.7M+87.3% | $18.5M+130.2% | -$61.3M+82.5% | -$349.9M |
JAZZ Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.7B | $1.4B-2.9% | $1.4B+27.8% | $1.1B-14.1% | $1.3B+63.4% | $778.5M-13.5% | $899.6M+15.9% | $776.4M-2.8% | $798.9M+15.3% | $693.1M+17.0% | $592.4M+11.4% | $531.9M+30.5% | $407.6M+41.3% | $288.4M+15.5% | $249.8M+64.7% | $151.6M |
| Capital Expenditures | $69.8M | $58.8M+54.3% | $38.1M+58.9% | $24.0M-17.5% | $29.0M+5.1% | $27.6M+84.2% | $15.0M-62.6% | $40.1M+97.0% | $20.4M-29.6% | $28.9M+198.9% | $9.7M-73.1% | $36.0M-1.1% | $36.3M+264.3% | $10.0M+66.9% | $6.0M+367.2% | $1.3M |
| Free Cash Flow | $1.6B | $1.3B-4.5% | $1.4B+27.1% | $1.1B-14.1% | $1.2B+65.5% | $750.9M-15.1% | $884.6M+20.2% | $736.3M-5.4% | $778.5M+17.2% | $664.1M+14.0% | $582.7M+17.5% | $496.0M+33.6% | $371.3M+33.3% | $278.5M+14.2% | $243.8M+62.2% | $150.3M |
| Investing Cash Flow | -$221.9M | -$1.5B-197.1% | -$508.2M-211.7% | -$163.1M+63.5% | -$446.2M+91.4% | -$5.2B-417.2% | -$1.0B-548.9% | -$155.3M+60.6% | -$394.5M-46.7% | -$268.9M+84.6% | -$1.8B-77556.5% | -$2.3M+99.8% | -$1.1B-6464.5% | -$16.3M+95.9% | -$395.3M-386.6% | -$81.2M |
| Financing Cash Flow | -$1.0B | -$873.4M-4357.1% | $20.5M+106.7% | -$305.3M+42.3% | -$529.5M-113.3% | $4.0B+651.9% | $528.1M+279.8% | -$293.7M+38.7% | -$479.1M-17.1% | -$409.1M-175.6% | $541.0M+352.4% | -$214.3M-130.1% | $711.0M+3080.5% | -$23.9M-105.3% | $448.5M+1455.8% | -$33.1M |
| Share Buybacks | N/A | $125.0M-59.9% | $311.4M+15.4% | $269.8M+499457.4% | $54K | $0-100.0% | $146.5M-51.4% | $301.4M-42.4% | $523.7M+430.0% | $98.8M-64.5% | $278.3M+352.1% | $61.6M+45.8% | $42.2M-69.1% | $136.5M | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
JAZZ Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -10.1%-27.7pp | 17.6%+2.5pp | 15.1%+16.9pp | -1.8%-7.3pp | 5.5%-10.5pp | 16.0%-8.6pp | 24.6%-7.9pp | 32.5%-0.2pp | 32.7%-7.1pp | 39.8%+1.4pp | 38.4%+21.7pp | 16.7%-22.3pp | 39.0%+5.2pp | 33.8%-13.2pp | 46.9% |
| Net Margin | -8.3%-22.1pp | 13.8%+2.9pp | 10.8%+16.9pp | -6.1%+4.5pp | -10.7%-20.8pp | 10.1%-14.1pp | 24.2%+0.6pp | 23.6%-6.5pp | 30.1%+3.5pp | 26.7%+1.8pp | 24.9%+19.9pp | 5.0%-19.8pp | 24.8%-24.5pp | 49.3%+3.3pp | 45.9% |
| Return on Equity | -8.3%-21.9pp | 13.7%+2.6pp | 11.1%+18.4pp | -7.3%+1.0pp | -8.3%-14.8pp | 6.5%-10.3pp | 16.8%+0.6pp | 16.2%-1.8pp | 18.0%-3.2pp | 21.1%+1.8pp | 19.3%+15.0pp | 4.3%-12.4pp | 16.7%-9.0pp | 25.7%-39.1pp | 64.8% |
| Return on Assets | -3.0%-7.7pp | 4.7%+1.0pp | 3.6%+5.7pp | -2.1%+0.6pp | -2.7%-6.3pp | 3.6%-5.8pp | 9.4%+0.9pp | 8.6%-0.9pp | 9.5%+1.3pp | 8.3%-1.6pp | 9.9%+8.1pp | 1.8%-7.9pp | 9.7%-5.0pp | 14.7%-34.6pp | 49.3% |
| Current Ratio | 1.86-2.6x | 4.46+2.2x | 2.24-0.6x | 2.79-0.4x | 3.23-1.1x | 4.34-0.1x | 4.47+0.9x | 3.57+0.3x | 3.29+0.4x | 2.91-2.6x | 5.55+0.9x | 4.69+0.4x | 4.24+1.4x | 2.88-0.9x | 3.77 |
| Debt-to-Equity | 1.00-0.5x | 1.48+0.1x | 1.37-0.5x | 1.85+0.3x | 1.52+1.0x | 0.510.0x | 0.51-0.1x | 0.570.0x | 0.57-0.5x | 1.06+0.4x | 0.67-0.3x | 0.97+0.6x | 0.420.0x | 0.38+0.4x | 0.00 |
| FCF Margin | 30.4%-3.0pp | 33.4%+5.5pp | 27.9%-6.1pp | 34.0%+9.7pp | 24.3%-13.2pp | 37.4%+3.4pp | 34.1%-7.1pp | 41.2%+0.1pp | 41.0%+1.9pp | 39.2%+1.7pp | 37.4%+5.8pp | 31.6%-0.3pp | 31.9%-9.7pp | 41.6%-13.6pp | 55.2% |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Where Jazz Pharmaceuticals Plc Ranks
Frequently Asked Questions
What is Jazz Pharmaceuticals Plc's annual revenue?
Jazz Pharmaceuticals Plc (JAZZ) reported $4.3B in total revenue for fiscal year 2025. This represents a 4.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Jazz Pharmaceuticals Plc's revenue growing?
Jazz Pharmaceuticals Plc (JAZZ) revenue grew by 4.9% year-over-year, from $4.1B to $4.3B in fiscal year 2025.
Is Jazz Pharmaceuticals Plc profitable?
No, Jazz Pharmaceuticals Plc (JAZZ) reported a net income of -$356.1M in fiscal year 2025, with a net profit margin of -8.3%.
What is Jazz Pharmaceuticals Plc's EBITDA?
Jazz Pharmaceuticals Plc (JAZZ) had EBITDA of -$388.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Jazz Pharmaceuticals Plc have?
As of fiscal year 2025, Jazz Pharmaceuticals Plc (JAZZ) had $1.4B in cash and equivalents against $4.3B in long-term debt.
What is Jazz Pharmaceuticals Plc's operating margin?
Jazz Pharmaceuticals Plc (JAZZ) had an operating margin of -10.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Jazz Pharmaceuticals Plc's net profit margin?
Jazz Pharmaceuticals Plc (JAZZ) had a net profit margin of -8.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Jazz Pharmaceuticals Plc's return on equity (ROE)?
Jazz Pharmaceuticals Plc (JAZZ) has a return on equity of -8.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Jazz Pharmaceuticals Plc's free cash flow?
Jazz Pharmaceuticals Plc (JAZZ) generated $1.3B in free cash flow during fiscal year 2025. This represents a -4.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Jazz Pharmaceuticals Plc's operating cash flow?
Jazz Pharmaceuticals Plc (JAZZ) generated $1.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Jazz Pharmaceuticals Plc's total assets?
Jazz Pharmaceuticals Plc (JAZZ) had $11.7B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Jazz Pharmaceuticals Plc's capital expenditures?
Jazz Pharmaceuticals Plc (JAZZ) invested $58.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Jazz Pharmaceuticals Plc spend on research and development?
Jazz Pharmaceuticals Plc (JAZZ) invested $782.7M in research and development during fiscal year 2025.
What is Jazz Pharmaceuticals Plc's current ratio?
Jazz Pharmaceuticals Plc (JAZZ) had a current ratio of 1.86 as of fiscal year 2025, which is generally considered healthy.
What is Jazz Pharmaceuticals Plc's debt-to-equity ratio?
Jazz Pharmaceuticals Plc (JAZZ) had a debt-to-equity ratio of 1.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Jazz Pharmaceuticals Plc's return on assets (ROA)?
Jazz Pharmaceuticals Plc (JAZZ) had a return on assets of -3.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Jazz Pharmaceuticals Plc's Altman Z-Score?
Jazz Pharmaceuticals Plc (JAZZ) has an Altman Z-Score of 1.87, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Jazz Pharmaceuticals Plc's Piotroski F-Score?
Jazz Pharmaceuticals Plc (JAZZ) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Jazz Pharmaceuticals Plc's earnings high quality?
Jazz Pharmaceuticals Plc (JAZZ) reported a net loss of $356.1M while generating $1.4B in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Jazz Pharmaceuticals Plc?
Jazz Pharmaceuticals Plc (JAZZ) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.